CTI BioPharma Investor Relations Material
Latest events
Q4 2022
CTI BioPharma
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from CTI BioPharma Corp
Access all reports
CTI BioPharma Corp. is a biopharmaceutical company that acquires, develops and commercializes novel targeted therapies for blood-related cancers in the United States. The Company's product candidates include bevacizumab/dexrazoxane, rapamycin and bortezomib/dexrazoxane that have demonstrated efficacy in preclinical and clinical studies.
Latest articles
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Puig's 2024 IPO: Paco Rabanne, Jean Paul Gaultier, and Beyond
Explore Puig's journey from its 1914 inception to a 2024 IPO, showcasing its growth, strategic acquisitions, and impact in the beauty and fashion industry.
15 Apr 2024
Ticker symbol
Country
🇺🇸 United States